



## CORRESPONDENCE

# Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’

*British Journal of Cancer* (2018) 118:1154; <https://doi.org/10.1038/s41416-018-0032-y>

We thank Sauerbrei and Haeussler<sup>1</sup> for their interest in our paper<sup>2</sup> and their methodological comments. Our aim was to undertake these analyses and draw some conclusions from the available literature regarding the prognostic significance of BAG-1 in breast cancer, given multiple studies. We felt that this was important, particularly since BAG-1 is already included in multi-gene assays widely used as part of routine clinical practice and due to ongoing investigation into the possibility of inhibition of BAG-1 function as a potential therapeutic strategy. We did not use the supplementary information provided within the REMARK Explanation and Elaboration paper.<sup>3</sup> We provided our interpretation whether details within the REMARK checklist were included in the papers and, as we highlighted, the literature reviewed was heterogeneous and with a range in study quality. We believe our conclusions were drawn with appropriate caveats to highlight this.

### ADDITIONAL INFORMATION

**Competing interests:** The authors declare no competing interests.

**Note:** This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International licence (CC BY 4.0).

E. S. Papadakis<sup>1</sup>, T. Reeves<sup>1</sup>, N. H. Robson<sup>1</sup>, T. Maishman<sup>2</sup>,  
G. Packham<sup>1</sup> and R. I. Cutress<sup>1,3</sup>

<sup>1</sup>*Cancer Research UK Centre Cancer Sciences Unit, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK;*  
<sup>2</sup>*Southampton Clinical Trials Unit, University of Southampton, Southampton SO17 1BJ, UK and* <sup>3</sup>*University Hospital Southampton, University of Southampton Faculty of Medicine, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK*  
Correspondence: T Reeves (T.Reeves@soton.ac.uk)

### REFERENCES

1. Sauerbrei W, Haeussler T. Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’. *Br. J. Cancer* <https://doi.org/10.1038/s41416-018-0023-z> (2018).
2. Papadakis, E. S. et al. BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. *Br. J. Cancer* **116**, 1585–1594, <https://doi.org/10.1038/bjc.2017.130> (2017).
3. Altman, D. G., McShane, L. M., Sauerbrei, W. & Taube, S. E. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. *BMC Med.* **10**, 51 (2012).

Received: 11 January 2018 Revised: 22 January 2018 Accepted: 22 January 2018  
Published online: 15 March 2018